Quantcast
Last updated on April 18, 2014 at 6:54 EDT

Latest autoimmune diseases Stories

2013-10-01 23:04:08

HB 1183, which passed the General Assembly and was signed into law by Governor Martin O’Malley on April 18, 2013 expands access to an “employee only” bathroom in retail establishments for Ostomy patients as well as individuals suffering from Crohn’s Disease, Ulcerative Colitis, and other medical conditions that require immediate access to a restroom, when no public restroom facilities are otherwise available. Rockville, MD (PRWEB) October 01, 2013 Metro Maryland Ostomy...

2013-10-01 23:00:18

Arthritis Relief Miracle is one of the best natural remedies for arthritis pain that helps people get rid of arthritis once and for all. A complete overview on the website Vkool.com shows users whether or not Arthritis Relief Miracle is really effective. Seattle, WA (PRWEB) October 01, 2013 Arthritis Relief Miracle was created by Connie Carmen, a female medical researcher,who has spent 12 years researching arthritis. This remedy is among the best natural remedies for arthritis pain that...

2013-10-01 16:24:29

MONROVIA, Calif., Oct. 1, 2013 /PRNewswire/ -- Xencor, Inc. today announced that the first patient has been dosed in the Phase 2a part of its ongoing Phase 1b/2a clinical trial of XmAb®5871 in patients with active rheumatoid arthritis. XmAb5871 is the first in Xencor's class of therapeutic antibodies targeting the FcgRIIb pathway in B cells, which shows potential to suppress autoimmune disorders without the side effects caused by B cell depletion. XmAb5871 is an Fc engineered...

2013-10-01 08:32:06

Be Joint Smart educates public about devastating disease affecting 100,000 Pennsylvanians PORTLAND, Ore., Oct. 1, 2013 /PRNewswire-USNewswire/ -- For the second year, the National Psoriasis Foundation and the Arthritis Foundation will partner to educate Americans about psoriatic arthritis, a chronic, inflammatory autoimmune disease that affects roughly 100,000 Pennsylvanians and about 45,000 Philadelphia Metro residents. The two organizations present the first psoriatic-arthritis specific...

2013-09-30 23:27:33

Reportbuyer.com just published a new market research report: Multiple Sclerosis: KOL Insight. London (PRWEB) September 30, 2013 An incisive report and dynamic analyst briefing service delivering insight from the most influential Multiple Sclerosis (MS) Key Opinion Leaders to map the current treatment landscape and analyse future trends. The past year has seen landmark changes in multiple sclerosis, with the launch of two new novel oral products—Tecfidera (dimethyl fumarate; Biogen...

2013-09-30 12:53:40

Brings to 110 known risk factors and provides important insight into disease mechanism Scientists of the International Multiple Sclerosis Genetics Consortium (IMSGC) have identified an additional 48 genetic variants influencing the risk of developing multiple sclerosis. This work nearly doubles the number of known genetic risk factors and thereby provides additional key insights into the biology of this debilitating neurological condition. The genes implicated by the newly identified...

2013-09-30 12:27:30

Rheumatologists Expect More Extensive Clinical Trials for Biosimilars than Gastroenterologists, According to a New Report from BioTrends Research Group EXTON, Penn., Sept. 30, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that the majority of surveyed gastroenterologists do not expect to prescribe an infliximab biosimilar, such as Celltrion's Remsima, in their Crohn's disease (CD)...

2013-09-30 12:25:03

America's largest lupus walk program raises funds for lupus research and education programs in the Los Angeles area LOS ANGELES, Sept. 30, 2013 /PRNewswire-USNewswire/ -- Celebrities turned out to support the Lupus Foundation of America's Walk to End Lupus Now(TM) this weekend in Los Angeles, to raise money towards research and education programs, increase awareness of the devastating autoimmune disease, and rally public support for those who suffer from its brutal impact. Comedian...

2013-09-30 08:30:20

- GL-2045 is Gliknik's Lead Recombinant Stradomer(TM) Designed to Improve on Pooled Human Intravenous Immunoglobulin - BALTIMORE, Sept. 30, 2013 /PRNewswire/ -- Gliknik Inc., a privately held biopharmaceutical company, today announced that it has entered into an exclusive worldwide licensing agreement with Pfizer Inc. for GL-2045, Gliknik's recombinant stradomer(TM), a drug candidate that is designed to replace and improve on pooled human intravenous immunoglobulin (IVIG). GL-2045...

2013-09-30 08:28:39

- Approval is supported by data from the RAPID(TM)-PsA study and represents the third U.S. indication for Cimzia® BRUSSELS, Sept. 30, 2013 /PRNewswire/ -- regulated information - UCB announced today that the U.S. Food and Drug Administration (FDA) has approved Cimzia(® )(certolizumab pegol) for the treatment of adult patients with active psoriatic arthritis (PsA). "The FDA's approval of Cimzia(®) for the treatment of active PsA provides an additional, effective treatment option for those...